^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NTRK1-KHDRBS1 fusion

    i
    Other names: NTRK1, MTC, TRK, TRKA, Neurotrophic tyrosine kinase, receptor, type 1, KHDRBS1, KH RNA Binding Domain Containing, Signal Transduction Associated 1, Src-Associated In Mitosis 68 KDa Protein, Sam68, KH Domain-Containing, RNA-Binding, Signal Transduction-Associated Protein 1, P21 Ras GTPase-Activating Protein-Associated P62, GAP-Associated Tyrosine Phosphoprotein P62, P62, P68, KH Domain Containing, RNA Binding, Signal Transduction Associated 1, GAP-Associated Tyrosine Phosphoprotein P62 (Sam68), F
    Entrez ID:
    4914; 10657
    Related biomarkers:
    Expression
    Mutation
    Fusion
    Others
    almost3years
    Unclassified mesenchymal sarcoma with NTRK1-KHDRBS1 gene fusion: a case report of long-term tumor-free survival with crizotinib treatment. (PubMed, World J Surg Oncol)
    This case will be of significant interest to pathologists because, despite the tumor being unclassified, a molecular target was identified. Although the FDA does not currently approve crizotinib for treatment of patients harboring NTRK gene fusions, this case provides new insights for diagnosis and treatment of mesenchymal sarcomas with NTRK1 gene translocations. Similar to ALKomas, which can be successfully treated using NTRK molecular-targeted therapy, tumors with NTRK gene translocations can be classified as NTRKomas, even when they occur at different organ sites, and with varying histological morphologies, and immunophenotypes.
    Clinical • Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • KHDRBS1 (KH RNA Binding Domain Containing, Signal Transduction Associated 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK1 fusion • ALK translocation • NTRK1-KHDRBS1 fusion • NTRK fusion
    |
    Xalkori (crizotinib)